Immutep Limited Announces Constructive Feedback Has Been Received From The Paul-Ehrlich-Institut Regarding The Planned TACTI-004 Phase III Trial Of Eftilagimod Alpha For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer

Author: Benzinga Newsdesk | December 21, 2023 09:04am

Among the other items discussed at the meeting were general aspects of the trial design, including selection of the control arm and the potential patient population as defined by level of PD-L1 expression. Additional interactions with the U.S. Food and Drug Administration (FDA), other local European regulators, as well as with other stakeholders and potential partners are ongoing. Immutep plans to announce its final trial design for TACTI-004 in Q1 of CY2024.

Posted In: IMMP